HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CBD Regulation Bill Filed In US House Again; VMS In Pre-Tax Savings Accounts In First Senate Vote

Executive Summary

Hemp-Derived CBD bill either provides exact solution US needs for lawful use of cannabinoids as dietary ingredients or falls well short, depending on the trade group. Legislation to expand health savings accounts to include vitamin, mineral and supplement products reached Senate floor vote before failing.

You may also be interested in...



Hitching A Ride Could Be Legislative Route For Adding Supplements To Pre-tax Savings Accounts

Support from members of both parties is a good start, supplement industry trade groups say, but reaching a finish line of passing a bill on its own doesn’t appear likely in 2021, while the odds might be better on adding the legislation as a provision to a broader bill.

After Aligning With FDA On Cannabinoids, California Lawmakers Move On Lawful Use

State Senate scheduled to vote on bill on 8 September and Assembly later in week. Floor votes prompted by amendment removing language that banned hemp smokables in the state, replaced by a phase-in approach.

Expanding Crop Of Ingredients Could Shrink Support For Lawful Use Of Hemp In Supplements

Groups of House and Senate members who opposed legislation to de-schedule hemp as a controlled substance in 2018 remain opposed to also legalizing cannabis and could stifle support for making lawful hemp’s use in supplements.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

RS150980

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel